Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Ku, ShengYu ^a   Lasorsa, Elena ^a   Adelaiye, Remi ^a   Ramakrishnan, Swathi ^a   Ellis, Leigh ^a   Pili, Roberto ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; DOCETAXEL; HEAT SHOCK PROTEIN 90; LUMINESPIB; 5-(2,4-DIHYDROXY-5-ISOPROPYLPHENYL)-4-(4-MORPHOLIN-4-YLMETHYLPHENYL)ISOXAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE; ANTINEOPLASTIC AGENT; ISOXAZOLE DERIVATIVE; PROTEASOME; RESORCINOL DERIVATIVE; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CASTRATION RESISTANT PROSTATE CANCER; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; REGULATORY MECHANISM; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG COMBINATION; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HSP90 HEAT-SHOCK PROTEINS; ISOXAZOLES; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, ANDROGEN; RESORCINOLS; TAXOIDS; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 84904969593     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103680     Document Type: Article

References (35)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512. (Pubitemid 39315317)
2. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, et al. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376: 1147-1154.
3. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005.
5. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, et al. (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: 1187-1197.
6. Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, et al. (2013) Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer 11: 20-26.
7. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549.
8. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, et al. (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8: 986-993. (Pubitemid 34517631)
9. Vanaja DK, Mitchell SH, Toft DO, Young CY (2002) Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 7: 55-64. (Pubitemid 36138904)
10. Gandhi N, Wild AT, Chettiar ST, Aziz K, Kato Y, et al. (2013) Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biol Ther 14: 347-356.
11. Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, et al. (2011) Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res 71: 5838-5849.
12. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, et al. (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23: 4152-4161. (Pubitemid 46211321)
13. Heath EI, Gaskins M, Pitot HC, Pili R, Tan W, et al. (2005) A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer 4: 138-141. (Pubitemid 41474610)
14. Ramanathan RK, Egorin MJ, Erlichman C, Remick SC, Ramalingam SS, et al. (2010) Phase I pharmacokinetic and pharmacodynamic study of 17-dimethyla- minoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol 28: 1520-1526.
15. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P (1999) DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91: 1940-1949.
16. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, et al. (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68: 2850-2860. (Pubitemid 351556284)
17. Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, et al. (2012) Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res 18: 3562-3570.
18. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, et al. (2008) NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 10: R33.
19. Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Pili R (2012) Development of a castrate resistant transplant tumor model of prostate cancer. Prostate 72: 587-591.
20. Liao CP, Liang M, Cohen MB, Flesken-Nikitin A, Jeong JH, et al. (2010) Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors. Horm Cancer 1: 44-54.
21. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, et al. (1996) Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 2: 1039-1048.
22. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, et al. (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4: 223-238. (Pubitemid 37163836)
23. Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, et al. (2005) Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res 65: 11565-11571. (Pubitemid 41821715)
24. Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10: 194-204.
25. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58. (Pubitemid 37328807)
26. Berrieman HK, Lind MJ, Cawkwell L (2004) Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 5: 158-164. (Pubitemid 38262847)
27. Georget V, Terouanne B, Nicolas JC, Sultan C (2002) Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 41: 11824-11831.
28. O'Malley KJ, Langmann G, Ai J, Ramos-Garcia R, Vessella RL, et al. (2012) Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance. Prostate 72: 1117-1123.
29. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, et al. (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23: 1078-1087. (Pubitemid 46202262)
30. Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, et al. (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23: 1885-1893. (Pubitemid 46211366)
31. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, et al. (2008) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14: 7940-7946.
32. Iyer G, Morris MJ, Rathkopf D, Slovin SF, Steers M, et al. (2012) A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol 69: 1089-1097.
33. Morikawa Y, Koike H, Sekine Y, Matsui H, Shibata Y, et al. (2012) Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation. Biochem Biophys Res Commun 419: 584-589.
34. Brubaker KD, Brown LG, Vessella RL, Corey E (2006) Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 6: 15.
35. Galsky MD, Vogelzang NJ (2010) Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 21: 2135-2144.